Alcohol withdrawal nursing: CIWA-Ar, delirium tremens, and safe management

Alcohol withdrawal is one of the few withdrawal syndromes that can kill. When a patient who has been drinking heavily stops — whether by choice, illness, injury, or hospital admission — the brain that learned to compensate for years of CNS depressant exposure suddenly loses its chemical brake. The result is a cascade of autonomic hyperactivity that, without skilled nursing assessment and rapid pharmacological intervention, can progress to seizures, delirium tremens, and death. Up to 15% of patients who develop delirium tremens (DTs) die if left untreated.

Nurses are the first line of defense. They administer the CIWA-Ar every hour during acute withdrawal, titrate benzodiazepines, ensure thiamine is given before any glucose, and watch for the red flags that mean a patient needs an ICU bed before the next assessment. This guide covers the clinical protocol from pathophysiology through discharge education, with full CIWA-Ar and benzodiazepine tables and 20 high-yield NCLEX tips.

For the broader context of alcohol use disorder — including diagnostic criteria, epidemiology, and pharmacotherapy for long-term abstinence — see the substance use disorders nursing overview.

Pathophysiology of alcohol withdrawal

Understanding why withdrawal is dangerous requires understanding what chronic alcohol use does to the brain at the neurotransmitter level.

GABAergic suppression

Alcohol is a CNS depressant. Its primary mechanism is potentiation of gamma-aminobutyric acid (GABA) at the GABA-A receptor — the brain’s main inhibitory neurotransmitter. With chronic heavy alcohol exposure, the brain adapts by down-regulating GABA receptor density and sensitivity. The brain requires ever-increasing amounts of alcohol to produce the same inhibitory effect, and ambient GABA activity drops.

When alcohol is abruptly removed, GABA inhibition collapses. There is no longer enough inhibitory tone to hold the excitatory systems in check.

Glutamatergic hyperexcitability

In parallel, chronic alcohol up-regulates glutamate receptors — specifically NMDA (N-methyl-D-aspartate) receptors, the brain’s primary excitatory system. During drinking, this up-regulation is a compensatory counter to alcohol’s GABA enhancement. When alcohol disappears, both changes converge: GABA inhibition is suppressed, and glutamate excitation is amplified. The result is profound CNS hyperexcitability — the neurochemical engine of every symptom of alcohol withdrawal.

This explains why symptoms escalate predictably over time, why seizures appear before DTs (cortical hyperexcitability precedes brainstem dysregulation), and why benzodiazepines — which enhance GABA — are the mainstay of pharmacotherapy. Nothing else addresses the root mechanism as directly.

Autonomic storm

The locus coeruleus — the brain’s primary noradrenergic nucleus — is also released from inhibition. The result is a catecholamine surge: elevated heart rate, blood pressure, temperature, and respiratory rate. In severe withdrawal, this autonomic storm drives the life-threatening features of delirium tremens. Clonidine can blunt the noradrenergic component but cannot prevent seizures and is never a substitute for benzodiazepines in alcohol withdrawal.

AWS timeline: what to expect and when

Alcohol withdrawal syndrome (AWS) follows a relatively predictable timeline, though the rate of progression varies significantly based on years of heavy drinking, prior withdrawal episodes (kindling effect), concurrent medical illness, and polypharmacy.

The kindling effect is a critical clinical concept. Each withdrawal episode sensitizes the brain and makes subsequent withdrawals more severe. A patient who previously had “mild” withdrawals may develop seizures or DTs during a later episode. Always treat prior withdrawal history as a prognostic factor, not reassurance.

Risk factors for severe AWS include daily drinking of >8 drinks, prior DT episodes, concurrent liver disease, electrolyte abnormalities on admission, and older age. Patients meeting these criteria warrant admission even if presenting with mild initial CIWA-Ar scores.

CIWA-Ar protocol: nursing administration and scoring

The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is the validated instrument for quantifying AWS severity and guiding benzodiazepine dosing. It contains 10 items scored on scales of 0–7 (most items) with a maximum total score of 67.

Assessment frequency:

• Acute phase (CIWA-Ar ≥8 or within 24–48 hours of last drink): every 1 hour
• Stable/improving (CIWA-Ar consistently <8 for 8+ hours): every 2–4 hours
• Mild (CIWA-Ar <8 with no seizure risk): every 4–8 hours per protocol

The nurse administers the CIWA-Ar, records the score, and triggers pharmacotherapy per the standing orders (usually: score 8–14 = moderate dose benzodiazepine; score ≥15 = higher dose + physician notification; score ≥20 = urgent escalation).

Interpreting CIWA-Ar scores

• Score <8 (mild): Monitor, support, hydrate, oral thiamine. Pharmacotherapy may not be required per protocol — follow physician orders.
• Score 8–14 (moderate): Administer benzodiazepine per standing order. Increase assessment frequency.
• Score ≥15 (severe): Administer higher-dose benzodiazepine; notify physician immediately.
• Score ≥20: Escalate to urgent intervention. Consider ICU transfer. Prepare for possible seizure.

Symptom-triggered vs fixed-schedule dosing

Symptom-triggered dosing (benzodiazepine given only when CIWA-Ar reaches threshold) results in significantly less total benzodiazepine use, shorter treatment duration, and fewer complications than fixed-schedule dosing in patients who can be reliably assessed every hour. Most evidence supports symptom-triggered dosing as the preferred approach for patients without prior seizure history who can cooperate with CIWA-Ar administration.

Fixed-schedule dosing (benzodiazepine given on a set schedule regardless of CIWA-Ar) is reserved for patients who cannot cooperate with assessment (cognitive impairment, language barrier, prior severe withdrawal/DTs, co-occurring delirium), or when nursing resources make hourly CIWA-Ar monitoring impractical.

When to notify the physician

Notify immediately for:

• CIWA-Ar ≥15 (severe AWS)
• Any new-onset seizure activity
• Temperature >38.5°C (101.3°F) with tachycardia and altered mentation (DTs developing)
• Respiratory depression after benzodiazepine administration (over-sedation)
• CIWA-Ar not responding to two escalating doses of benzodiazepine
• Evidence of concurrent infection, liver failure, or GI bleeding that may complicate management

COWS scale: opioid withdrawal nursing

The Clinical Opiate Withdrawal Scale (COWS) is the parallel assessment tool for opioid withdrawal syndrome — often administered alongside CIWA-Ar in patients with polysubstance use. It contains 11 items and is nurse-administered, with scoring guiding comfort medication.

Key difference from alcohol withdrawal: Opioid withdrawal, while intensely distressing, is almost never fatal in otherwise healthy adults. The autonomic symptoms (tachycardia, diaphoresis, piloerection, mydriasis, hypertension) are similar in appearance but carry far less immediate lethality risk. Exceptions include severe dehydration from vomiting and diarrhea, particularly in immunocompromised or elderly patients.

COWS items (11 total): Resting pulse rate; sweating; restlessness/agitation; pupil size; bone or joint aches; runny nose/tearing; GI upset; tremor; yawning; anxiety or irritability; gooseflesh skin (piloerection).

COWS score interpretation:

• 5–12: Mild withdrawal
• 13–24: Moderate withdrawal
• 25–36: Moderately severe withdrawal
• ≥36: Severe withdrawal

Nursing role in COWS: Administer every 4–8 hours (or per protocol), document score, administer comfort medications per orders (clonidine for autonomic symptoms, dicyclomine or loperamide for GI cramping, antiemetics, NSAIDs or acetaminophen for musculoskeletal pain). If methadone or buprenorphine induction is planned, confirm COWS score meets threshold (typically ≥8–12) before the first dose to avoid precipitated withdrawal.

Benzodiazepine management

Benzodiazepines are the cornerstone of AWS pharmacotherapy. They enhance GABA-A receptor activity, directly counteracting the GABA down-regulation and glutamate hyperexcitability that drive withdrawal. No other class of medications has equivalent evidence for preventing withdrawal seizures and DTs. See the psychiatric medications nursing guide for a broader review of benzodiazepine pharmacology.

Nursing monitoring during benzodiazepine administration

• Respiratory rate and SpO2 before and 30–60 minutes after each IV dose. Target SpO2 ≥94%.
• Level of consciousness using RASS or similar scale. Goal during acute phase is calm, easily arousable (RASS 0 to -1) — not deeply sedated.
• Blood pressure and heart rate — benzodiazepines should blunt the autonomic surge. If vitals fail to respond despite adequate dosing, notify physician.
• Over-sedation signs: slurred speech, respiratory rate <10, RASS ≤-3, oxygen desaturation. If present: stop benzodiazepine dosing; call rapid response if SpO2 falls; have flumazenil (reversal agent) available but use cautiously in chronic benzodiazepine users as it may precipitate seizures.
• Ensure IV access with patent line before any IV benzodiazepine.

Thiamine (vitamin B1): always before glucose

This is a non-negotiable nursing priority. Administer thiamine 100 mg IV or IM before any IV dextrose, IV fluids containing glucose, or oral food.

Why this matters: Chronic alcohol use causes severe thiamine (vitamin B1) deficiency through poor dietary intake, impaired intestinal absorption, reduced hepatic storage, and increased urinary excretion. Thiamine is essential for glucose metabolism — specifically the pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase reactions in the Krebs cycle. Administering glucose to a thiamine-deficient patient forces these enzymatic reactions without the cofactor, rapidly depleting whatever thiamine remains and precipitating Wernicke’s encephalopathy.

Wernicke’s encephalopathy is a medical emergency characterized by the classic triad: confusion/altered mental status, ocular abnormalities (nystagmus, lateral rectus palsy, conjugate gaze palsy), and ataxia. If untreated, it progresses to Korsakoff’s syndrome — a permanent amnestic disorder with confabulation and inability to form new memories. Korsakoff’s syndrome is largely irreversible; Wernicke’s, if caught early and treated aggressively with thiamine, is partially reversible.

Dosing: Standard prophylactic dose is 100 mg IM or IV daily. For suspected Wernicke’s, high-dose IV thiamine (500 mg three times daily for 3 days) is recommended before reverting to standard dosing.

Route: IM or IV preferred in acute AWS — GI absorption is unreliable due to nausea, vomiting, and alcohol-related intestinal damage.

Nursing priorities and safety

Alcohol withdrawal management extends well beyond the CIWA-Ar and benzodiazepines. The following priorities must run in parallel during all phases of care. For the broader framework of nursing safety priorities, see the delegation and prioritization nursing guide.

Fall prevention

Tremors, ataxia, altered mentation, and benzodiazepine sedation all dramatically increase fall risk. Implement fall precautions from admission: bed alarm activated, bed in lowest position, call light within reach, non-slip footwear, and hourly rounding. For patients with CIWA-Ar ≥15, 1:1 observation or sitter should be requested. See the fall prevention nursing guide for the full protocol.

Seizure precautions

All alcohol withdrawal patients are at risk for seizures. Implement seizure precautions from the outset: padded side rails, suction equipment at bedside, oxygen at bedside, IV access confirmed patent. During any seizure, do not restrain — position laterally, protect the airway, time the seizure, and notify physician. See seizure nursing management for the complete protocol. Post-ictal confusion is expected; document duration and all seizure characteristics.

Environmental management

Stimuli amplify AWS severity. Provide a quiet, dimly lit room. Minimize unnecessary interruptions. Calm, unhurried nursing communication reduces anxiety scores and CIWA-Ar item values. Reorientation to time and place reduces disorientation scores.

Telemetry and monitoring

Patients with CIWA-Ar ≥15, prior DT history, or severe autonomic instability require continuous cardiac monitoring. Tachycardia, hypertension, and QTc prolongation may develop. Document vital signs q1h during acute phase.

IV access and fluids

Ensure at least one patent IV access. Patients are frequently volume-depleted from diaphoresis, vomiting, and poor oral intake. Administer normal saline or lactated Ringer’s per orders. Avoid excessive free water — hyponatremia may complicate severe AWS.

Electrolyte replacement

Electrolyte derangements are near-universal in alcohol withdrawal and amplify seizure risk and cardiac instability:

• Hypomagnesemia — most common and most important. Magnesium is required for potassium reabsorption; hypomagnesemia causes refractory hypokalemia. Replace IV per protocol.
• Hypokalemia — correct to K+ ≥3.5 mEq/L. Worsens cardiac arrhythmia risk.
• Hypophosphatemia — causes respiratory muscle weakness; replace per protocol.
• Hyponatremia — may be dilutional or from poor intake. Monitor sodium daily; correct cautiously (rate ≤8–10 mEq/L/24h to avoid osmotic demyelination).

Nutritional supplementation

In addition to thiamine, administer:

• Folic acid (folate) 1 mg PO daily — alcohol depletes folate stores, impairing RBC production and CNS function.
• Multivitamin — B-complex vitamins broadly depleted in chronic alcohol use.
• NPO (nothing by mouth) for patients with altered mentation, vomiting, or aspiration risk. Advance diet as tolerated once mental status clears.

Aspiration precautions

Vomiting combined with altered mentation creates a high aspiration risk. Position patient at 30–45 degrees when possible. Have suction at bedside. Document airway patency and respiratory status with each assessment. For patients with reduced gag reflex, ensure oral medications are held until swallowing is safe.

Delirium tremens: emergency management

Delirium tremens (DTs) represents the most severe phase of alcohol withdrawal. It is characterized by:

• Global confusion and disorientation — patient cannot identify place, time, or situation
• Severe autonomic instability — temperature >38.5°C, heart rate >120, systolic BP >160, diaphoresis
• Agitation — often extreme; patient may pull out lines, fall out of bed, or become combative
• Hallucinations — predominantly visual and tactile; differ from alcoholic hallucinosis in that sensorium is impaired (patient does not know the hallucinations are unreal)

DTs typically begin 48–96 hours after the last drink and may last 1–5 days. For management of the altered mental status component, see the delirium nursing guide.

Escalation sequence

1. High-dose benzodiazepine loading: Lorazepam (Ativan) 2–4 mg IV every 5–15 minutes until agitation is controlled; or diazepam 5–10 mg IV. Document total cumulative dose and response.
2. ICU transfer criteria: DTs with respiratory compromise, failure to respond to initial benzodiazepine loading (>40 mg diazepam equivalent without adequate sedation), temperature >40°C, hemodynamic collapse.
3. Phenobarbital for benzodiazepine-refractory DTs — a GABA-B agonist that acts at a different receptor site, allowing synergistic sedation without simply escalating benzodiazepine dose. Requires close respiratory monitoring.
4. Propofol infusion in ICU for refractory DTs when standard benzodiazepines and phenobarbital fail to control agitation or when mechanical ventilation is required to protect the airway.

Opioid withdrawal management

Opioid withdrawal management is a parallel competency for nurses caring for patients with polysubstance use or those presenting for opioid use disorder treatment.

Pharmacological options:

• Methadone — full mu-opioid agonist; suppresses withdrawal; requires specialized licensure to prescribe for OUD treatment in the outpatient setting, but can be administered in inpatient settings. Carry risk of QTc prolongation — baseline ECG before starting.
• Buprenorphine (Suboxone, Subutex) — partial mu-opioid agonist/kappa antagonist; highly effective for withdrawal management and maintenance. Administer only when COWS ≥8–12 (patient is in established withdrawal) to avoid precipitating withdrawal in methadone-maintained patients. Sublingual route; assess for adequate dissolution before proceeding.
• Clonidine — alpha-2 adrenergic agonist; blunts autonomic symptoms (tachycardia, hypertension, diaphoresis, restlessness) but does not address the opioid receptor deficit. Monitor blood pressure closely — hypotension is the primary adverse effect. Not FDA-approved for OUD but widely used adjunctively.

Supportive care:

• Antiemetics (ondansetron, promethazine) for nausea and vomiting
• Antidiarrheals (loperamide) for cramping and loose stools
• NSAIDs or acetaminophen for myalgias and bone pain
• Hydroxyzine or low-dose benzodiazepine for severe anxiety (use cautiously — many OUD patients have concurrent CNS depressant use)
• Adequate hydration — monitor for dehydration from vomiting and diarrhea

Differential diagnosis

Several conditions mimic or complicate alcohol withdrawal. Failure to recognize the differential can lead to missed diagnoses and inadequate treatment.

Hepatic encephalopathy: Patients with chronic liver disease may present with confusion, agitation, and altered mentation that appears similar to AWS. Key differentiators: asterixis (flapping tremor) is characteristic of hepatic encephalopathy, not AWS; elevated serum ammonia; the tremor pattern differs (hepatic flap is present at rest, AWS tremor worsens with action); jaundice, ascites, and other stigmata of chronic liver disease. Management is ammonia reduction (lactulose, rifaximin), not benzodiazepines — which can worsen hepatic encephalopathy. See the hepatic encephalopathy nursing guide.

Neuroleptic malignant syndrome (NMS): Hyperthermia, rigidity, altered mental status, and autonomic instability — can appear similar to severe DTs. NMS is triggered by antipsychotic medications (particularly dopamine antagonists) or abrupt withdrawal from dopaminergic agents. Lead pipe rigidity and elevated CK are hallmarks. No seizures. Management: dantrolene, dopamine agonists.

Septic encephalopathy: Delirium, autonomic instability, and agitation in a febrile, ill-appearing patient can mimic DTs. Always evaluate for infection source — pneumonia, UTI, SBP in cirrhotic patients, and bloodstream infection must be ruled out. Empirical antibiotics should not be delayed if septic encephalopathy is suspected.

Diabetic ketoacidosis (DKA): Altered mentation, diaphoresis, tachycardia, and nausea overlap. Point-of-care glucose distinguishes rapidly. Note that hypoglycemia is also common in alcohol withdrawal due to impaired gluconeogenesis — check fingerstick glucose on every patient presenting with AWS or altered mentation.

Wernicke’s encephalopathy: Can coexist with AWS and is frequently precipitated by glucose administration in thiamine-deficient patients. Always administer thiamine first. The classic triad (confusion, ophthalmoplegia, ataxia) is often incomplete — maintain a high index of suspicion in any patient with chronic alcohol use and altered mental status.

Patient education and harm reduction

Patient education during and after alcohol withdrawal must be non-judgmental, motivationally framed, and delivered when the patient is medically stable and cognitively accessible. The acute phase is not the time for extended counseling — brief, compassionate, present-focused communication is appropriate. For a full framework on therapeutic communication, see therapeutic communication nursing.

Language and documentation

Never use the word “alcoholic” in clinical documentation or patient interaction. The person-first, stigma-reducing language is alcohol use disorder (AUD) — a recognized DSM-5 diagnosis. This is not mere political correctness: stigmatizing language reduces treatment-seeking and is associated with worse provider attitudes and patient outcomes. Document “patient reports history of alcohol use disorder” rather than “patient is an alcoholic.”

Similarly, document “patient presented for detoxification” rather than “patient came in to dry out.” Precision matters in clinical records.

Motivational interviewing

Motivational interviewing (MI) is the evidence-based communication framework for addressing substance use. Core principles: express empathy, roll with resistance, support self-efficacy, develop discrepancy between the patient’s behavior and their own stated values and goals. MI does not lecture or argue — it elicits the patient’s own reasons for change.

Brief MI interventions in acute care settings (even 5–10 minutes) are associated with reduced drinking and increased treatment uptake at 3 and 6 months post-discharge.

SBIRT framework

SBIRT (Screening, Brief Intervention, Referral to Treatment) is the standard public health framework recommended by SAMHSA and the Joint Commission for substance use in healthcare settings:

• Screen every patient using a validated tool (AUDIT-C or CAGE questionnaire)
• Brief intervention for patients with risky or hazardous use — 5–15 minutes of MI-based discussion
• Referral to treatment for patients with moderate-to-severe AUD — warm handoff to social work, addiction medicine, or outpatient treatment program

Pharmacotherapy overview

Three FDA-approved medications support long-term alcohol abstinence. The detailed nursing pharmacology is covered in the substance use disorders nursing article; a brief orientation here:

• Naltrexone (Vivitrol) — mu-opioid receptor antagonist; reduces craving and the rewarding effects of alcohol; available PO daily or IM monthly. Contraindicated in acute opioid use (precipitates withdrawal).
• Acamprosate (Campral) — modulates glutamate/GABA balance; reduces protracted withdrawal symptoms and craving; dosed TID; renally cleared.
• Disulfiram (Antabuse) — inhibits aldehyde dehydrogenase; causes aversive reaction (flushing, nausea, tachycardia) when alcohol is ingested; requires motivated, supervised patients.

Harm reduction framing

Not every patient is ready for abstinence at discharge. Harm reduction is a valid, evidence-based approach that meets patients where they are. Interventions include: advising patients to reduce daily intake before the next visit, providing information on supervised consumption sites where available, ensuring patients know when to seek care (signs of withdrawal, injury), and connecting with peer support programs.

NCLEX high-yield: 20 tips

Clinical sources

• Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. “Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar).” British Journal of Addiction. 1989;84(11):1353–1357.
• Schuckit MA. “Recognition and management of withdrawal delirium (delirium tremens).” New England Journal of Medicine. 2014;371(22):2109–2113.
• Maldonado JR, Sher Y, Das S, et al. “Prospective validation study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS).” Alcohol and Alcoholism. 2015;50(5):509–518.
• American Society of Addiction Medicine (ASAM). The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. 2020.
• Kosten TR, O’Connor PG. “Management of drug and alcohol withdrawal.” New England Journal of Medicine. 2003;348(18):1786–1795.
• Saitz R. “Introduction to alcohol withdrawal.” Alcohol Health & Research World. 1998;22(1):5–12.
• Thomson AD, Cook CC, Touquet R, Henry JA. “The Royal College of Physicians report on alcohol: guidelines for managing Wernicke’s encephalopathy in the accident and emergency department.” Alcohol and Alcoholism. 2002;37(6):513–521.
• StatPearls. “Alcohol Withdrawal.” NCBI Bookshelf. Updated 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK441882/